32.00 0.00 (0.00%)
After hours: 6:20PM EDT
|Bid||31.90 x 800|
|Ask||32.00 x 4000|
|Day's Range||30.75 - 32.00|
|52 Week Range||14.85 - 32.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.80|
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?
Novocure (NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer.
Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31. Gert Lennart Perlhagen is retiring from the board after 15 years of service. “We are extremely pleased to welcome David and Sheri to our board,” said Bill Doyle, Novocure’s Executive Chairman.
WallStEquities.com has selected the following Medical Appliances and Equipment stocks for review this morning: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), and NuVasive Inc. (NASDAQ: NUVA). North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s shares gained slightly by 0.35%, closing Wednesday's trading session at $14.20.
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Novocure today reported financial results for the quarter and year ended March 31, 2018, highlighting year-over-year growth in active patients and net revenues. Novocure is a global oncology company developing a proprietary platform called Tumor Treating Fields for the treatment of solid tumor cancers.
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 26, 2018 at 8:00 AM Eastern Time. To listen ...
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Neovasc Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Novocure announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall survival and progression free survival among patients who received Tumor Treating Fields plus standard of care chemotherapy, pemetrexed and cisplatin or carboplatin, compared to historical control data of patients who received standard of ...
Novocure announced today that new data on Tumor Treating Fields will be presented at the American Association for Cancer Research Annual Meeting 2018, which will be held April 14 through April 18, in Chicago.
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$1.96B. However, an important fact which most ignore is: how financially healthyRead More...
Novocure announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2018, at 8 a.m.
Novocure announced today that the National Comprehensive Cancer Network has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma in its globally recognized Clinical Practice Guidelines in Oncology for Central Nervous System Cancers.
Stock Monitor: CryoLife Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
NovoCure Limited’s (NASDAQ:NVCR): NovoCure Limited engages in the development, manufacture, and commercialization of Tumor Treating Fields for the treatment of solid tumors. The US$2.00B market-cap company announced a latest lossRead More...
Novocure announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018, April 14 through April 18, in Chicago.